Arthritis Group — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$93,639	25
2022	Research	$30,061	1
2021	Research	$180,505	1
2020	Research	$62,348	17
2019	Research	$21,053	14

Breakdown

Who paid Research payments · program years 2019–2023

Amgen Inc. $245,944 7 payments
GRT US Holding, Inc. $93,639 25 payments
Pfizer Inc. $31,057 20 payments
Eli Lilly and Company $16,102 4 payments
Celgene Corporation $864 2 payments

Studies the money was for Research payments · program years 2019–2023

Psa-013/20200058 (Keg) (Foremost) $180,505 1 payment
A Randomized Doubleblind Placebocontrolled Phase III Trial to Evaluate the Efficacy and Safety of A Single Intraarticular Injection of Rtxgrt7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee $93,639 25 payments
Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) $35,039 3 payments
Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $31,057 20 payments
Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG $30,061 1 payment
A Phase 3 Multicenter Study to Evaluate the Long Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis $16,102 4 payments
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ? 1 Conventional Synthetic DMARD (CC-10004-PSA-013) $607 1 payment
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST) $257 1 payment
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ? 1 Conventional Synthetic DMARD $257 1 payment
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. FOREMOST $83 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.